Type 2 Diabetes - DPP-IV Inhibitors Will Be the Main Class to Benefit Following the Suspension of Pioglitazone Use in Fran

  • Pioglitazone use will continue to decrease
  • GLP-1 agonists are most used in the large US market with 11% of patients
  • First-in-class brands lead the field in both DPP-IV inhibitor (Januvia) and GLP-1 agonist (Byetta) classes

LONDON--(BUSINESS WIRE)-- Pioglitazone use will continue to decrease, but most expect to increase their prescribing of DPP-IV inhibitors and GLP-1 agonists, according to a new report available on companiesandmarkets.com.

Hot Topics in Type 2 Diabetes: Physician Perceptions of Incretin Mimetics and TZDs - Physician Survey Provides Insights into TZD, DPP-IV, and GLP-1 Usage
http://www.companiesandmarkets.com/Market-Report/hot-topics-in-type-2-diabetes-physician-perceptions-of-incretin-mimetics-and-tzds-physician-survey-provides-insights-into-tzd,-dpp-iv,-and-glp-1-usage-633150.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

Key opinion leaders believe that DPP-IV inhibitors will be the main class to benefit following the June 2011 suspension of pioglitazone use in France and Germany because of a link with bladder cancer.

Class use varies greatly among the seven major markets. Pioglitazone is still highly used in the US and Italy, but DPP-IV inhibitors have overtaken pioglitazone by share in the other markets. GLP-1 agonists are most used in the large US market with 11% of patients.

First-in-class brands lead the field in both DPP-IV inhibitor (Januvia) and GLP-1 agonist (Byetta) classes. Januvia is likely to maintain its lead based on a longer safety record and the perceived lack of differentiation in the class, but Byetta has rapidly lost class share to later market entrant Victoza.

Prescribing practices for the key branded non-insulin classes – TZDs, DPP-IV inhibitors, and GLP-1 agonists – vary widely among the seven major markets. We surveyed 199 primary care physicians and specialists across markets on type 2 diabetes treatment choices.

* Analyze country-specific physician insight on non-insulin antidiabetic use by line of therapy.

* Compare physician-reported trends and patient shares in TZD, DPP-IV inhibitor and GLP-1 agonist use by class.

* Use key opinion leader insight to explain reported trends and unmet needs

* Identify opportunities to target underserved markets and physician cohorts

* Delve into primary data from 199 seven major market physicians on current usage and future trends of TZDs, DPP-IV inhibitors, and GLP-1 agonists.

* Use key opinion leader insight to elucidate differences in prescribing practices

* Identify the different opportunities in the type 2 diabetes treatment algorithm

Report Details: http://www.companiesandmarkets.com/Market-Report/hot-topics-in-type-2-diabetes-physician-perceptions-of-incretin-mimetics-and-tzds-physician-survey-provides-insights-into-tzd,-dpp-iv,-and-glp-1-usage-633150.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Paul Chapman
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe  France  Germany

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Diabetes

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.